Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P628: Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Huguet M.1, Pereira B.2, Goutte M.1,3, Goutorbe F.1,4, Allimant C.1, Reymond M.1, Bommelaer G.1,3, Buisson A.*1,3

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France 2University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France 3UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France 4Hospital of Bayonne, Gastroenterology Department, Bayonne, France

P629: Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one yearECCO '17 Barcelona
Year: 2017
Authors:

Rodríguez Glez G.E.*1, Díaz Hernández L.1, Morales Barrios J.A.2, Vela González M.1, Tardillo Marín C.A.1, Viña Romero M.M.2, Rodríguez Díaz C.Y.1, Arranz Hernández L.1, Hernández Camba A.1, Merino Alonso F.J.2, Pérez Hernández F.1

1Hospital Universitario Ntra. Sra. Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain 2Hospital Universitario Ntra. Sra. Candelaria, Pharmacology, Santa Cruz de Tenerife, Spain

P630: The long-term efficacy of adalimumab on Crohn's disease comorbid with perianal lesions and poor prognostic factor analysisECCO '17 Barcelona
Year: 2017
Authors:

Nozaki R., Goto H., Tsuji Y., Takano S., Yamada K., Takano M.

Coloproctology Center, Takano Hospital, Kumamoto, Japan

P631: Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in inflammatory bowel diseasesECCO '17 Barcelona
Year: 2017
Authors:

Bibani N., Yakoubi M., Sabbah M., Trad D., Ouakaa A., Gargouri D., Elloumi H., Kharrat J.

Habib Thameur Hospital, Gastro enterology, Tunis, Tunisia

P632: Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Juan G.*1, Mora M.2, Alvariño A.3, Maroto N.2, Ferrer I.2, Hinojosa E.2, Hinojosa M.D.2, Ferrandis P.1, Hinojosa J.2

1Hospital de Manises, Department of Pharmacy, Manises, Spain 2Hospital de Manises, IBD Unit, Manises, Spain 3Hospital de Manises, Department of Labratory, Manises, Spain

P633: Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Fiorino G.*1, Ruiz-Agüello M.B.2, Maguregui A.2, Nagore D.2, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Martínez A.2, Danese S.1,3

1Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy 2Progenika Biopharma SA, R&D Department, Derio, Spain 3Humanitas University, Department of Biomedical Sciences, Milan, Italy

P634: Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

García Ortíz J.M., Sáenz Gallo M., Trigo Salado C., De La Cruz Ramirez M.D., Marquez Galan J.L., Herrera Justiniano J.M., Bozada García J.M., Leo Carnerero E.

HU Virgen del Rocío, UGC Digestive Diseases, Seville, Spain

P635: Enteral nutrition in the treatment of young adults with active Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Wall C.*1, Gearry R.2, Day A.1

1University of Otago Christchurch, Department of Paediatrics, Christchurch, New Zealand 2University of Otago, Christchurch, Department of Medicine, Christchurch, New Zealand

P636: Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapyECCO '17 Barcelona
Year: 2017
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

1Hospital de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal 2Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P637: Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical responseECCO '17 Barcelona
Year: 2017
Authors:

Dreesen E.*1, Van Stappen T.1, Ballet V.2, Tops S.1, Compernolle G.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

1KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Campus Gasthuisberg, Department of Gastroenterology and Hepatology, Leuven, Belgium

P638: Release of 5-aminosalicylic acid from mesalazine formulations: a novel dynamic dissolution model simulating gastrointestinal pH changesECCO '17 Barcelona
Year: 2017
Authors:

Demyanova E.1, Vakhitov T.1, Sitkin S.*1,2

1State Research Institute of Highly Pure Biopreparations, Dept. of Microbiology, St. Petersburg, Russian Federation 2North-Western State Medical University named after I.I. Mechnikov, Dept. of Internal Diseases, Gastroenterology & Dietetics, St. Petersburg, Russian Federation

P639: Switching from originator-infliximab to biosimilar-Infliximab in IBD-patients does not lead to significant changes in infliximab trough levelsECCO '17 Barcelona
Year: 2017
Authors:

Eberl A.*1,2, Huoponen S.2, Pahikkala T.3, Arkkila P.1,2, Blom M.2, Sipponen T.1,2

1Helsinki University Central Hospital - Meilahti Hospital, Department of Gastroenterology, Helsinki, Finland 2University of Helsinki, Biomedicum 2C, Helsinki, Finland 3Unversity of Turku, Department of Information Technology, Turku, Finland

P640: Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective studyECCO '17 Barcelona
Year: 2017
Authors:

Rowan C.R.*1, Kalei A.2, De Vries A.2, Cullen G.3,4, Ryan E.1,4, Mulcahy H.3,4, D'Haens G.5, Doherty G.A.3,4

1St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland 2Sanquin Blood Supply - Diagnostic Services, Biologicals Laboratory, Amsterdam, Netherlands 3St Vincent's University Hospital, Department of Gastroenterology and Centre for Colorectal Disease, Dublin, Ireland 4University College Dublin, School of Medicine, Dublin, Ireland 5Academic Medical Center (AMC), Department of Gastroenterology, Amsterdam, Netherlands

P641: Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's disease: a hospital-based cohort study from KoreaECCO '17 Barcelona
Year: 2017
Authors:

Seo H.*1, Ye B.D.1,2, Lee S.-H.1, Chang K.1, Song E.M.1, Kim G.-U.1, Seo M.1, Lee H.-S.3, Hwang S.W.1,2, Park S.H.1,2, Yang D.-H.1, Kim K.-J.1,2, Byeon J.-S.1, Myung S.-J.1, Yang S.-K.1,2

1University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea 2University of Ulsan College of Medicine, Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, South Korea 3University of Ulsan College of Medicine, Asan Medical Center, Health Screening and Promotion Center, Seoul, South Korea

P642: Impact of histological and endoscopic remission in clinical recurrence and recurrence-free time in ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Ponte A., Pinho R., Fernandes S., Rodrigues A., Alberto L., Silva J., Rodrigues J., Sousa M., Leite S., Silva A.P., Proença L., Freitas T., Carvalho J.

Centro Hospitalar Vila Nova de Gaia/Espinho, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova Gaia, Portugal

P643: Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Rasmussen M.*1, Brynskov J.1, Ainsworth M.A.1, Buhl S.1, Bendtzen K.2, Steenholdt C.1

1Copenhagen University Hospital Herlev, Department of Gastroenterology, Herlev Copenhagen, Denmark 2Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark

P644: Factors and salvage surgery for treatment of pouch failure after restorative proctocolectomy for ulcerative colitis – a single-institution studyECCO '17 Barcelona
Year: 2017
Authors:

Kuroki H., Sugita A., Koganei K., Tatsumi K., Futatsuki R., Obara N.

Yokohama Municipal Citizen's Hospital, Inflammatory Bowel Disease Center, Yokohama City, Japan

P645: The introduction of infliximab therapeutic drug level monitoring for is associated with cost savings in a cohort of patients in a large district general hospitalECCO '17 Barcelona
Year: 2017
Authors:

Whiteoak S., Johnson H., Hovell C., Weaver S., McLaughlin S.

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

P646: Low FODMAPs diet as a magic bullet in reducing symptoms in different gastrointestinal diseasesECCO '17 Barcelona
Year: 2017
Authors:

Testa A., Imperatore N., Rispo A., Capone P., Rea M., Nardone O.M., Opramolla A., Tortora R., Caporaso N., Castiglione F.

University “Federico II” of Naples, Department of Clinical Medicine and Surgery, Naples, Italy

P647: Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case seriesECCO '17 Barcelona
Year: 2017
Authors:

Zerôncio M.*1, Blake A.2, Rana-Khan Q.3, Palo W.4, Bhayat F.5

1Clínica de Oncologia de Natal, Gastroenterology, Natal, Brazil 2Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 3Takeda Pharmaceutical International AG Singapore, Emerging Markets Medical Affairs, Singapore, Singapore 4Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States 5Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom